Tranexamic Acid to Reduce Infection After Gastrointestinal Surgery
Launched by BAYSIDE HEALTH · Dec 8, 2019
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether a medication called Tranexamic Acid (TxA) can help reduce the risk of infections after gastrointestinal (GI) surgery. The trial will include about 3,300 adult patients from Australia and other countries who are having major GI surgeries, such as operations on the esophagus, stomach, or intestines. To participate, patients need to be between the ages of 65 and 74 or younger than 36, and they should have certain health risk factors, like being over 70, having heart or breathing issues, being obese, or having low levels of hemoglobin (the protein in blood that carries oxygen).
Participants in this trial will receive either TxA or a placebo (a similar-looking substance that does not contain the medication) for comparison. The study is designed to reflect real-world medical practices, which means doctors will use their judgment when caring for patients during the trial. Patients will be monitored closely for any effects of the medication and to see if it helps in preventing infections after surgery. It’s important for potential participants to understand that this trial is focused on improving patient outcomes in surgery, especially for those at higher risk of complications.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- 1. Adult patients scheduled for elective or semi-elective (inpatient) open or lap-assisted GI surgery (oesophageal, gastric, hepatobiliary, colorectal) with one or more risk factors for complications:
- • Age ≥70 years
- • ASA physical status 3 or 4
- • Known or suspected history of: heart failure, diabetes, peripheral vascular disease, or chronic respiratory disease
- • Obesity (BMI ≥30 kg/m2)
- • Anaemia (preoperative haemoglobin \<130 g/l in males and \<120 g/l in females)
- • Renal impairment (se. creatinine ≥150mol/l)
- • Low albumin (\<30 g/L)
- Exclusion Criteria:
- • Poor spoken and or written language comprehension
- • Laparoscopic cholecystectomy and other minor (eg. closure of stoma) surgery
- • Pre-existing infection/sepsis
- • Known history of: spontaneous pulmonary embolism, arterial thrombosis familial thrombophilia (e.g. Lupus anticoagulant, protein C deficiency, factor V Leiden)
About Bayside Health
Bayside Health is a leading clinical trial sponsor dedicated to advancing medical research and innovation through rigorous and ethical study design. With a focus on improving patient outcomes, Bayside Health collaborates with healthcare professionals, researchers, and institutions to conduct high-quality clinical trials across a diverse range of therapeutic areas. Committed to transparency and regulatory compliance, the organization prioritizes patient safety and data integrity, ensuring that all trials contribute valuable insights to the medical community and enhance the development of new treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Patients applied
Trial Officials
Paul S Myles, MD, DSc
Study Chair
Alfred Hospital and Monash University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials